Mutation-specific therapies and drug repositioning in cystic fibrosis

Area of Science:

• Genetics and Molecular Biology
• Pharmacology
• Rare Diseases

Background:

• Cystic fibrosis (CF) is a rare, inherited disease impacting over 85,000 individuals globally.
• Over 2000 loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause CF.
• Current treatments focus on managing symptoms, but etiological therapies are emerging.

Purpose of the Study:

• To review recent advancements in etiological therapies for CF.
• To discuss the role of CFTR modulators in repairing CFTR functional defects.
• To explore mutation-specific treatments and drug repositioning strategies for CF.

Main Methods:

• Literature review of recent research on CFTR modulators and therapeutic strategies.
• Analysis of mutation-specific treatments targeting CFTR biogenesis.
• Evaluation of drug repositioning for CF patient care.

Main Results:

• CFTR modulators represent a significant advance in treating the root cause of CF.
• Mutation-specific therapies are being developed to address diverse CFTR gene defects.
• Drug repositioning offers a promising avenue for circumventing CFTR dysfunction.
• Combined therapies show potential for greater clinical benefit in CF patients.

Conclusions:

• CFTR modulators are a promising etiological therapy for cystic fibrosis.
• Personalized, mutation-specific treatments combined with drug repositioning are crucial.
• Multidrug approaches are necessary to achieve significant clinical benefits for the CF population.